Abstract: Objective To evaluate the efficacy of lamivudine treatment in patients with chronic hepatits B and analysis of predicting factor. Methods Ninety patients with chronic hepatitis B were treated with lamivudine for 48 weeks. Results 21 patients （21.3%） had complete response （CR），64 patients （71.1%） had partial response （PR） and 5 patients（5.6%） were non- response（NR） in the 90 patients at the end of the regimen；In patients with baseline serum ALT≥2×upper limit of normal（ULN） and with HBeAg-negative，the rates of CR and virological response were higher，while the serum HBV DNA load had no predicting value；In 79 patients with baseline HBeAg-positive，HBeAg negativity rate was 29.6% and HBeAg/anti-HBe seroconversion rate was 9.9%；Gender and hepatitis B infection of family members were not related to the efficacy. Conclusion Lamivudine is effective in treatment of patients with chronic hepatitis B and the baseline serum ALT， HBeAg status and early response at 4 weeks have a predicting value for 48 week efficacy.

Key words: Hepatitis B, Lamivudine, Response